Irbesartan vs CYP2C8 Substrates (High risk)

Interacting Drugs
Irbesartan
vs
CYP2C8 Substrates (High risk)
Security Level
Minor, Monitor Therapy
Mechanism
CYP2C8 Substrates (High risk): CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates (High risk).
Management
Monitor therapy

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Irbesartan vs CYP2C8 Substrates (High risk)


Other Interactions of Irbesartan

We are Developing Our database, More results coming soon.